<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099021</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00862</org_study_id>
    <secondary_id>NCI-2009-00862</secondary_id>
    <secondary_id>CDR0000393562</secondary_id>
    <secondary_id>2001LS068</secondary_id>
    <secondary_id>0109 M 07254</secondary_id>
    <secondary_id>N01-CN-15000</secondary_id>
    <secondary_id>N01CN15000</secondary_id>
    <nct_id>NCT00099021</nct_id>
  </id_info>
  <brief_title>Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia</brief_title>
  <official_title>A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well pioglitazone hydrochloride works in preventing head and
      neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of
      certain drugs to try to prevent the development or recurrence of cancer. The use of
      pioglitazone hydrochloride may be effective in preventing head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine whether pioglitazone (pioglitazone hydrochloride) reverses leukoplakia in
      patients with hyperplastic or dysplastic oral cavity or oropharyngeal leukoplakia.

      SECONDARY OBJECTIVES:

      I. Determine the safety and tolerability of this drug in these patients.

      OUTLINE: This is an open-label study.

      Patients receive pioglitazone hydrochloride orally (PO) once daily (QD) for 12 weeks in the
      absence of disease progression, unacceptable toxicity, or the development of carcinoma.

      Patients are followed up at 4, 8, 12, and 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' Overall Response</measure>
    <time_frame>Week 16 (4 weeks post dose)</time_frame>
    <description>Overall Response= reviewing both the clinical and histological responses and assigning the worst category.
Complete Response (CR) = Clinical CR and Histologic CR, or Histologic CR Partial Response (PR) = Clinical CR or PR and Histologic PR or Stable Disease (SD) Stable Disease (SD) = Clinical SD and Histologic PR or SD Progressive Disease (PD) = Clinical PD and/or Histologic PD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' Clinical Response</measure>
    <time_frame>Week 16 (4 weeks post dose)</time_frame>
    <description>Determined by measurement of lesions- Complete Response (CR)= disappearance of all lesions, Partial Response (PR)= &gt;or= 50% decrease in sum of lesions, Stable Disease (SD) = does not meet CR,PR or Progressive Disease (PD), and PD= &gt;or= 25% increase in sum of lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' Histological (Tissue) Response</measure>
    <time_frame>Week 16 (4 weeks post dose)</time_frame>
    <description>Determined by biopsy results before and 4 weeks after treatment: Complete Response (CR) =complete reversal of dysplasia or hyperplasia, Partial Response (PR) = &gt;or=50% decrease in sum of lesions, no increase in 1 or more lesions and no new lesion occurs, Stable Disease (SD0 = not CR, PR or Progressive Disease (PD), PD = &gt;or= 25% increase in sum of lesions or new lesion or progression to invasive carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nf Kappa B p65</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ki 67 Labeling Index</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apotosis (Cell Death)</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pigliotazone Gamma Immune Histochemistry</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclooxygenase-2 Staining</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclin D1 and p21 Immune Histochemistry</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Involucrin and Transglutaminase Staining</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Oil Red O, AP2 (FABP4) and FABP5 Staining</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6, 8 and Vascular Endothelial Growth Factors Elaboration in the Oral Cavity and Serum</measure>
    <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
    <description>Quantitative studies of serum and saliva components for a pre and post treatment possible biomarker.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Oral Leukoplakia</condition>
  <arm_group>
    <arm_group_label>Prevention (pioglitazone hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Prevention (pioglitazone hydrochloride)</arm_group_label>
    <other_name>Actos</other_name>
    <other_name>pioglitazone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  ECOG 0-2

          -  Diagnosis of oral cavity or oropharyngeal leukoplakia meeting 1 of the following
             criteria:

          -  Biopsy-proven hyperplasia in high-risk anatomic areas (e.g., floor of the mouth,
             mobile tongue, oropharynx, or in any erythroplakia lesion)

          -  Mild, moderate, or severe dysplasia at any site of the oral cavity or oropharynx
             within the lesion

          -  Measurable lesion that is clinically characterized by leukoplakia, erythroplakia, or
             erythroleukoplakia

          -  Able to be assessed by bi-directional measurements

          -  Life expectancy: More than 3 months

          -  Hemoglobin &gt;= lower limit of normal for males and post-menopausal females OR

          -  Hemoglobin &gt;= 11 g/dL for premenopausal females

          -  WBC &gt; 3,000/mm^3

          -  Hepatic: Bilirubin &lt; 1.5 times upper limit of normal (ULN); AST and ALT &lt; 1.5 times
             ULN

          -  Renal: BUN &lt; 1.5 times ULN; Creatinine &lt; 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception

          -  No contraindication to thiazolidinediones

          -  No allergy to pioglitazone or other thiazolidinediones

          -  No serious oral infection

          -  No invasive carcinoma within the past 60 months except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No concurrent malignancy

          -  More than 3 months since prior biologic or immunologic therapy

          -  No concurrent insulin for diabetes

          -  No prior radiotherapy to the oral cavity

          -  More than 3 months since prior chemopreventative agents

          -  More than 3 months since prior experimental therapy

          -  More than 3 months since prior megadose vitamins or alternative therapy

          -  No prior thiazolidinediones

          -  No prior participation in this study

          -  No concurrent pharmacologic treatment for diabetes

          -  Concurrent chronic use of non-steroidal anti-inflammatory drugs allowed

          -  Platelet count &gt; 125,000/mm^3

          -  Index lesion must be located in an anatomic site accessible by punch biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ondrey</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Medical Center-Fairview</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center-Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <results_first_submitted>October 13, 2009</results_first_submitted>
  <results_first_submitted_qc>October 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2009</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone Patients</title>
          <description>Patients with measurable leukoplakia who received all study medication (oral pioglitazone once daily for 12 weeks) and completed the trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone Patients</title>
          <description>Patients with measurable leukoplakia who received all study medication (oral pioglitazone once daily for 12 weeks) and completed the trial.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" lower_limit="27" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients' Overall Response</title>
        <description>Overall Response= reviewing both the clinical and histological responses and assigning the worst category.
Complete Response (CR) = Clinical CR and Histologic CR, or Histologic CR Partial Response (PR) = Clinical CR or PR and Histologic PR or Stable Disease (SD) Stable Disease (SD) = Clinical SD and Histologic PR or SD Progressive Disease (PD) = Clinical PD and/or Histologic PD</description>
        <time_frame>Week 16 (4 weeks post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Patients</title>
            <description>Patients with measurable leukoplakia who received all study medication (oral pioglitazone once daily for 12 weeks) and completed the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients' Overall Response</title>
          <description>Overall Response= reviewing both the clinical and histological responses and assigning the worst category.
Complete Response (CR) = Clinical CR and Histologic CR, or Histologic CR Partial Response (PR) = Clinical CR or PR and Histologic PR or Stable Disease (SD) Stable Disease (SD) = Clinical SD and Histologic PR or SD Progressive Disease (PD) = Clinical PD and/or Histologic PD</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial + Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients' Clinical Response</title>
        <description>Determined by measurement of lesions- Complete Response (CR)= disappearance of all lesions, Partial Response (PR)= &gt;or= 50% decrease in sum of lesions, Stable Disease (SD) = does not meet CR,PR or Progressive Disease (PD), and PD= &gt;or= 25% increase in sum of lesions</description>
        <time_frame>Week 16 (4 weeks post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Patients</title>
            <description>Patients with measurable leukoplakia who received all study medication (oral pioglitazone once daily for 12 weeks) and completed the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients' Clinical Response</title>
          <description>Determined by measurement of lesions- Complete Response (CR)= disappearance of all lesions, Partial Response (PR)= &gt;or= 50% decrease in sum of lesions, Stable Disease (SD) = does not meet CR,PR or Progressive Disease (PD), and PD= &gt;or= 25% increase in sum of lesions</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial + Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients' Histological (Tissue) Response</title>
        <description>Determined by biopsy results before and 4 weeks after treatment: Complete Response (CR) =complete reversal of dysplasia or hyperplasia, Partial Response (PR) = &gt;or=50% decrease in sum of lesions, no increase in 1 or more lesions and no new lesion occurs, Stable Disease (SD0 = not CR, PR or Progressive Disease (PD), PD = &gt;or= 25% increase in sum of lesions or new lesion or progression to invasive carcinoma.</description>
        <time_frame>Week 16 (4 weeks post dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Patients</title>
            <description>Patients with measurable leukoplakia who received all study medication (oral pioglitazone once daily for 12 weeks) and completed the trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients' Histological (Tissue) Response</title>
          <description>Determined by biopsy results before and 4 weeks after treatment: Complete Response (CR) =complete reversal of dysplasia or hyperplasia, Partial Response (PR) = &gt;or=50% decrease in sum of lesions, no increase in 1 or more lesions and no new lesion occurs, Stable Disease (SD0 = not CR, PR or Progressive Disease (PD), PD = &gt;or= 25% increase in sum of lesions or new lesion or progression to invasive carcinoma.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial + Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nf Kappa B p65</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ki 67 Labeling Index</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apotosis (Cell Death)</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pigliotazone Gamma Immune Histochemistry</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclooxygenase-2 Staining</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cyclin D1 and p21 Immune Histochemistry</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Involucrin and Transglutaminase Staining</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Oil Red O, AP2 (FABP4) and FABP5 Staining</title>
        <description>Immune histochemistry / tissue staining for a possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 6, 8 and Vascular Endothelial Growth Factors Elaboration in the Oral Cavity and Serum</title>
        <description>Quantitative studies of serum and saliva components for a pre and post treatment possible biomarker.</description>
        <time_frame>Pre (Day 0) and Post (Week 12) Treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of Pioglitazone through Week 16 (end of study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone Patients</title>
          <description>Patients with measurable leukoplakia who received all study medication (oral pioglitazone once daily for 12 weeks) and completed the trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bleeding gums, occasional</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Puffy eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Facial edema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pounding pulse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Transient elevated blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain, right side</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Stye-inside corner, right eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal bloating</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Black stools</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Increased heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oral canker sores</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oral cavity/gum pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Left eye crusty, burning, reddened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Strep throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST elevated</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Decreased uric acid</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Muscle stiffness, aches, myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadness, dizzy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain, mild stinging sensation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Shakey, tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>WBCs in urine, asymptomatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Post menopausal spotting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Groin pain right hernia site (wound)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nail splitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ulcer at old gallbladder incision site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was closed prior to full accrual because results were very good and funding was discontinued (R-01 application was filed.)
Immunohistochemistry (Outcomes #4 through #12) were not done due to laboratory limitations of time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Frank G. Ondrey, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-3200</phone>
      <email>ondre002@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

